News stories about Sabra Health Care REIT (NASDAQ:SBRA) have been trending somewhat positive on Friday, according to Accern. The research group identifies negative and positive press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Sabra Health Care REIT earned a news impact score of 0.23 on Accern’s scale. Accern also gave news coverage about the real estate investment trust an impact score of 47.530897106481 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the media stories that may have impacted Accern Sentiment Analysis’s rankings:
- FY2018 EPS Estimates for Sabra Health Care REIT Inc Decreased by Analyst (SBRA) (americanbankingnews.com)
- Sabra Health Care REIT Inc (SBRA) Forecasted to Earn Q1 2018 Earnings of $0.61 Per Share (americanbankingnews.com)
- Less Risky stock is less profitable: Sabra Health Care REIT, Inc. (SBRA) – Wallstreet Investorplace (wallstreetinvestorplace.com)
- American International Group Inc. Buys 18,172 Shares of Sabra Health Care REIT Inc (SBRA) (americanbankingnews.com)
- Swiss National Bank Boosts Holdings in Sabra Health Care REIT Inc (SBRA) (americanbankingnews.com)
Several analysts have issued reports on SBRA shares. SunTrust Banks reaffirmed a “buy” rating and issued a $25.00 price objective on shares of Sabra Health Care REIT in a research report on Friday, November 3rd. Jefferies Group reaffirmed a “hold” rating on shares of Sabra Health Care REIT in a research report on Thursday, December 21st. Zacks Investment Research downgraded shares of Sabra Health Care REIT from a “hold” rating to a “sell” rating in a research report on Wednesday, January 17th. Raymond James Financial reaffirmed a “hold” rating on shares of Sabra Health Care REIT in a research report on Wednesday, December 13th. Finally, ValuEngine downgraded shares of Sabra Health Care REIT from a “buy” rating to a “hold” rating in a research report on Friday, February 2nd. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $23.50.
Sabra Health Care REIT (NASDAQ:SBRA) last released its quarterly earnings results on Wednesday, February 21st. The real estate investment trust reported $0.57 earnings per share for the quarter, topping analysts’ consensus estimates of $0.30 by $0.27. Sabra Health Care REIT had a net margin of 39.04% and a return on equity of 7.19%. The business had revenue of $166.47 million during the quarter, compared to the consensus estimate of $158.82 million. research analysts expect that Sabra Health Care REIT will post 2.51 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Wednesday, February 28th. Stockholders of record on Thursday, February 15th were given a dividend of $0.45 per share. This represents a $1.80 dividend on an annualized basis and a dividend yield of 10.50%. The ex-dividend date of this dividend was Wednesday, February 14th. Sabra Health Care REIT’s payout ratio is currently 174.76%.
Sabra Health Care REIT Company Profile
Sabra Health Care REIT, Inc is a real estate investment trust. The Company, through its subsidiaries, owns and invests in real estate serving the healthcare industry. The Company’s segment includes investments in healthcare-related real estate properties. The Company’s primary business consists of acquiring, financing and owning real estate property to be leased to third-party tenants in the healthcare sector.
Receive News & Ratings for Sabra Health Care REIT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sabra Health Care REIT and related companies with MarketBeat.com's FREE daily email newsletter.